During the past decade, Osaka Rosai Hospital conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 5 clinical trials were completed, i.e. on average, 41.7% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 5 clinical trials were completed. i.e. 71.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Osaka Rosai Hospital" #1 sponsor was "Janssen Research & Development, LLC" with 5 trials, followed by "Pfizer" with 2 trials sponsored, "Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan" with 2 trials sponsored, "AbbVie" with 1 trials sponsored and "Bayer" with 1 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Osaka Rosai Hospital" #1 collaborator was "Tokyo Medical and Dental University" with 2 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "ICON plc" with 1 trials as a collaborator, "Johnson & Johnson K.K. Medical Company" with 1 trials as a collaborator and "Taiho Pharmaceutical Co., Ltd." with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Osaka Rosai Hospital" are "Colorectal Cancer" (3 trials), "Urinary Bladder Neoplasms" (3 trials), "Acute Myocardial Infarction" (1 trials), "Ankylosing Spondylitis" (1 trials) and "Atrial Fibrillation" (1 trials). Many other conditions were trialed in "Osaka Rosai Hospital" in a lesser frequency.

Most popular intervention types in "Osaka Rosai Hospital" are "Drug" (14 trials), "Biological" (3 trials), "Device" (2 trials), "Other" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Cetrelimab" (2 trials), "TAR-200" (2 trials), "UFT adjuvant chemotherapy" (2 trials) and "Apixaban 2.5 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Osaka Rosai Hospital" are 18 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Osaka Rosai Hospital". undefined are not yet recruiting, 5 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Osaka Rosai Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Osaka Rosai Hospital, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".